Clinical Trial Detail

NCT ID NCT02434354
Title A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.